Prokarium Secures £4.6M from Wellcome to Fund the Clinical Development of its Lead Vaccine Programme

Posted on by
  • Prokarium announced it has received an investment of £4.59 million from Wellcome to fund two clinical trials of its lead programme, Entervax™, a bivalent vaccine against enteric fever
  • Entervax™ is based on the Vaxonella® platform and is the combination of Prokarium’s proprietary strain ZH9 (Salmonella enterica serovar Typhi ZH9), which has been safely administered to 351 individuals including 101 children in the UK, US and Vietnam, plus a novel strain modified to express antigens specific to Salmonella Paratyphi